Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Predicting benefit from imatinib: are we close?

Leukemia & lymphoma - 1 Nov 2014

Gandhi Mitul D, Kaklamani Virginia G

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily B
Share to Benzamides
Share to Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Share to Organic Cation Transporter 1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Piperazines

Share to Polymorphism, Single Nucleotide

Share to Pyrimidines

Source

Identifiers

PMID: 24684225
DOI: 10.3109/10428194.2014.909041

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Predicting benefit from imatinib: are we close?PMID 24684225Read ↗

Imatinib: the promise of a "magic bullet" for cancer fulfilled.Semantic proximity Read ↗

Should we be surprised at the paucity of response to EGFR inhibitors?Semantic proximity Read ↗

Pre-transplant and transplant parameters predict long-term survival after hematopoietic cell transplantation using machine learningSemantic proximity Read ↗

Predicting the response of CML patients to tyrosine kinase inhibitor therapy.Semantic proximity Read ↗

Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemiaSemantic proximity Read ↗

Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.Semantic proximity Read ↗

Targeted therapy for patients with chronic myeloid leukemia: clinical trial experience and challenges in inter-trial comparisons.Semantic proximity Read ↗

Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemiaSemantic proximity Read ↗

A machine learning approach to predicting short-term mortality risk in patients starting chemotherapySemantic proximity Read ↗

Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients.Semantic proximity Read ↗

Chronic Myeloid Leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 ActivitySemantic proximity Read ↗

OCT1 and imatinib transport in CML: is it clinically relevant?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.